BROSSARD, Quebec, March 14, 2018 (GLOBE NEWSWIRE) — Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:ADK) (OTCQB:DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today the opening of a third eye screening clinic in California located at Chaparral Medical Group Health Management Wellness Center.
In 2010, Medicare launched an annual benefit to all their members at Chaparral’s Health Management Wellness Center. The goal is to help promote preventive care methods, emphasizing on how to prevent disease instead of treating disease. With that, Chaparral Medical Group has decided it will automatically include eye screening using our CARA platform for diabetic and pre-diabetic patient at their annual visit.
“Chaparral is introducing AI to enhance the overall value of the annual health examination to Medicare members by encompassing CARA as an additional screening test for the annual wellness program. It is estimated that Medicare currently has 44 million beneficiaries enrolled in the Medicare program, some 15 percent of U.S. population. Having Chaparral Medical Group as a trusted partner will help to deploy faster while meeting all the industry requirements,” said Yves-Stephane Couture, VP sales at DIAGNOS.
“By adding eye screening with retina anomalies detection, we are broadening our study for annual wellness visits. As DIAGNOS continues to develop new algorithms and detect more illness, it will significantly help us to prevent disease evolution and take early action. We are proud to use DIAGNOS’ state of the art technology and to benefit from the Artificial Intelligence in our daily fight against diseases and we look forward to using them at the Health Management Centre,” said Dr. Jeereddi Prasad MD, Diabetes Specialist, President, and Medical Director of Chaparral Medical Group.
About Chaparral Medical Group
Chaparral Medical Group is a 80 physicians multi-specialty group serving the communities of Claremont, La Verne, San Dimas, Fontana, Pomona, Rancho Cucamonga, Upland, Chino Hills and Diamond Bar in Southern California. Over 20 primary care physicians serve as the group’s clinical core, and work together with their medical and surgical specialists to provide outstanding care to the patient population Southern California. They have been serving the community since 1978 and their unwavering commitment to patient care and physician work satisfaction are what have driven them to become the most trusted and relied-upon group of physicians in their area.
CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA’s Artificial Intelligence, based on our FLAIRE technology, image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients, in real time and has been approved by regulatory authorities including Health Canada, US Food and Drug Administration, the European Union and others.
For further information, please contact:
|Mr. André Larente, President||Daniel Renaud or Thomas Renaud, Managing Directors|
|DIAGNOS Inc.||Arrowhead Business and Investment Decisions, LLC|
|Tel: 450-678-8882 ext. 224||Tel: +1 212 619 6889, ext. 7010|
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.